Efficacy of a device to narrow the coronary sinus in refractory angina.
Stefan Verheye, E Marc Jolicœur, Miles W Behan...
https://pubmed.ncbi.nlm.nih.gov/25651246/Actively Recruiting
Led by Shockwave Medical, Inc. · Updated on 2026-09-30
380
Participants Needed
97
Research Sites
235 weeks
Total Duration
Researchers are evaluating the safety and effectiveness of the Shockwave Reducer device for patients with refractory angina pectoris who have persistent chest pain despite maximum medical therapy and are unsuitable for revascularization. This study includes a randomized, double-blind, sham-controlled trial comparing the Shockwave Reducer implant to a placebo procedure, as well as a non-randomized registry for special patient groups such as those with right coronary artery ischemia, abnormal coronary flow reserve, or mobility impairments preventing exercise testing. Participants in the randomized trial are assigned to receive either the Shockwave Reducer implant or a sham procedure with no device implanted. The registry group includes patients treated with the Shockwave Reducer who do not meet randomization criteria. The study involves implantation procedures, with evaluations of heart function and ischemia before enrollment. The trial spans multiple centers and uses a parallel study design. During the study, participants will undergo assessments including exercise tolerance tests, coronary angiography, and imaging to measure ischemia and heart function. Researchers will monitor angina symptoms using the Canadian Cardiovascular Society Angina Score and evaluate safety and effectiveness at six months. Participants are followed up for adherence to therapy and clinical status. The total study duration extends up to the primary completion date in July 2027, with ongoing long-term monitoring until 2032.
CONDITIONS
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
C
COSIRA-II Study Team
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Shockwave Medical, Inc.
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Coronary Sinus Reducer (CSR) implantation | Sham implantation (no device) | Guideline‑Directed Medical Therapy (GDMT) |
|---|---|---|---|
| What it is | Implantation of a stainless‑steel Coronary Sinus Reducer device designed to narrow the coronary sinus and improve myocardial perfusion | Sham implantation procedure without delivery of the device | Maximally tolerated guideline‑directed anti‑anginal medical therapy is the established standard care when revascularization is not feasible |
| Role in trial | Investigational treatment arm | Randomized sham‑control arm | Reference current‑care medical therapy outside the trial |
| Primary use | Studied as device‑based treatment to relieve refractory angina unamenable to revascularization | Serves as control to assess device efficacy beyond placebo | Symptom relief using pharmacologic agents as first‑line management |
| How it is performed | Percutaneous implantation of the Reducer device into the coronary sinus | Simulated implantation without device deployment | Daily oral medications tailored to symptom control per guidelines |
| Evidence status | Prior sham‑controlled trials have shown symptom relief and improved CCS class and exercise capacity | Control arm establishes placebo‑controlled baseline | GDMT provides moderate symptom relief in refractory angina |
| Important risks | Device implantation is invasive and carries procedural risks | Invasive procedural risks without therapeutic device benefit | Medication side effects depend on chosen agents |
| Important limitations | Efficacy evidence is still emerging and limited to symptom relief; long‑term outcomes unknown | Not intended as therapeutic option; only for trial control | Standard therapies may not completely relieve refractory symptoms |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 6 months
Participants receive either the Shockwave Reducer implant or a sham procedure without device implantation in a randomized, double-blind manner.
Multiple visits including implantation and follow-up assessments
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Stefan Verheye, E Marc Jolicœur, Miles W Behan...
https://pubmed.ncbi.nlm.nih.gov/25651246/Maximillian T Bourdillon, Nils P Johnson, H V Skip Anderson
https://pubmed.ncbi.nlm.nih.gov/39668004/Robert M Bober, Nils P Johnson
https://pubmed.ncbi.nlm.nih.gov/38395338/Shockwave Medical, Inc.
Lead Sponsor